We have changed our visitation policy for the safety of our patients and staff. Click here for the updated visitation policy and click here for information about COVID-19.

[LCID Study Number: 2018-054]

A multicenter, open-label safety and efficacy study of ADS-5102 Amantadine extended release capsules in patients with multiple sclerosis and walking impairment.

The purpose of this study is to look at the long-term safety and efficacy of 274 mg of ADS-5102 taken once daily at bedtime, and to determine if the drug is tolerable and effective for patients with multiple sclerosis (MS) with walking impairment.

Primary Contact Email: [email protected]

Primary Contact Phone: 781-372-7194